Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.35 |
| ▸ | LPL | P06858 | 8/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | CLK3 | P49761 | 1/20 | 0.33 |
| ▸ | WNT1 | P04628 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL551592 | 0.91 | CHRNB2 (0.41) | CHRNB2CHRNA4LIPGLPLDGAT1 | |
| SCHEMBL3801908 | 0.89 | HRH3 (0.45) | CHRNB2CHRNA4LIPGLPLDGAT1 | |
| SCHEMBL3801108 | 0.89 | LIPG (0.45) | CHRNB2CHRNA4LIPGLPLDGAT1 | |
| SCHEMBL3792923 | 0.82 | DGAT1 (0.42) | CHRNB2CHRNA4LIPGLPLDGAT1 | |
| SCHEMBL4158398 | 0.81 | PRMT6 (0.40) | LIPGLPLDGAT1DYRK1AF11 | |
| SCHEMBL3803519 | 0.75 | MKNK1 (0.45) | LIPGLPLDGAT1F11FFAR1 | |
| SCHEMBL3796275 | 0.75 | LIPG (0.62) | LIPGLPLDGAT1 | |
| SCHEMBL3798360 | 0.75 | LIPG (0.49) | LIPGLPLDGAT1F11PRMT6 | |
| SCHEMBL12373176 | 0.75 | LPL (0.44) | LIPGLPLF11FFAR1 | |
| SCHEMBL2428673 | 0.74 | LIPG (0.45) | LIPGLPLDGAT1F11FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | CHRNB2 3774/4885CHRNA4 961/4885LIPG 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.